Incomplete Freund'S Adjuvant

Summary

Incomplete Freund’S Adjuvant (CHEMBL4650400) is a phase-3 clinical-stage unknown; indicated across 30 conditions including cutaneous melanoma and melanoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 30 conditions
• Clinical trials: 68

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4650400
Name	Incomplete Freund’S Adjuvant
Type	Unknown
Max phase	3

Also known as: Freund’s adjuvant incomplete, Incomplete freund’s adjuvant, Montanide isa 51, Montanide isa 51 vg, INCOMPLETE FREUND’S ADJUVANT

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

30 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cutaneous melanoma	3	MONDO:0005012	EFO:0000389
melanoma	3	MONDO:0005105	EFO:0000756
myelodysplastic syndrome	2	MONDO:0018881	EFO:0000198
glioblastoma	2	MONDO:0018177	EFO:0000519
prostate adenocarcinoma	2	MONDO:0005082	EFO:0000673
renal cell carcinoma	2	MONDO:0005086	EFO:0000681
exocrine pancreatic carcinoma	2	MONDO:0005192	EFO:0002618
ovarian neoplasm	2	MONDO:0021068	EFO:0003893
gliosarcoma	2	MONDO:0016681	EFO:1001465
gastric neoplasm	2	MONDO:0021085	MONDO:0001056
gallbladder neoplasm	2	MONDO:0021253	MONDO:0005411
ovarian cancer	2	MONDO:0008170	MONDO:0008170
lung neoplasm	2	MONDO:0021117	MONDO:0008903
skin neoplasm	2	MONDO:0002531	MONDO:0002898
multiple sclerosis	2	MONDO:0005301	MONDO:0005301
ocular melanoma	2	MONDO:0006325	EFO:1000403
colorectal neoplasm	2	MONDO:0005335	MONDO:0005575
acute myeloid leukemia	1	MONDO:0018874	EFO:0000222
chronic myeloid leukemia	1	MONDO:0011996	EFO:0000339
neoplasm	1	MONDO:0005070	EFO:0000616
plasma cell myeloma	1	MONDO:0009693	EFO:0001378
myelodysplastic syndrome with excess blasts	1	MONDO:0019454	EFO:0003811
plasma cell leukemia	1	MONDO:0018689	EFO:0006475
peritoneal neoplasm	1	MONDO:0006901	MONDO:0002087
fallopian tube neoplasm	1	MONDO:0021092	MONDO:0002158
breast neoplasm	1	MONDO:0021100	MONDO:0007254
Plasmodium vivax malaria	1	MONDO:0005921	EFO:0007445

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 68.

Phase distribution

Phase	Trials
PHASE2	41
PHASE1	18
PHASE1/PHASE2	4
EARLY_PHASE1	2
Not specified	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00019682	PHASE3	COMPLETED	Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
NCT02455557	PHASE2	ACTIVE_NOT_RECRUITING	SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
NCT07169617	PHASE2	NOT_YET_RECRUITING	Testing the SurVaxM Vaccine for Lung Cancer Prevention
NCT00001703	PHASE2	TERMINATED	Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma
NCT00001827	PHASE2	TERMINATED	p53 Vaccine for Ovarian Cancer
NCT00003222	PHASE2	COMPLETED	Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma
NCT00003274	PHASE2	COMPLETED	Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery
NCT00003339	PHASE2	COMPLETED	Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma
NCT00003362	PHASE2	COMPLETED	Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma
NCT00003568	PHASE2	COMPLETED	Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma
NCT00004918	PHASE1/PHASE2	COMPLETED	Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome
NCT00006385	PHASE2	COMPLETED	Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma
NCT00012246	PHASE2	TERMINATED	Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract
NCT00019383	PHASE2	COMPLETED	Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma
NCT00019487	PHASE2	COMPLETED	Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
NCT00019721	PHASE2	COMPLETED	Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
NCT00019994	PHASE2	COMPLETED	Vaccine Therapy in Treating Patients With Metastatic Melanoma
NCT00020358	PHASE2	COMPLETED	Vaccine Therapy in Treating Patients With Melanoma
NCT00021164	PHASE2	COMPLETED	Vaccine Therapy in Treating Patients With Metastatic Cancer
NCT00022438	PHASE2	COMPLETED	Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma That Has Not Responded to Previous Treatment
NCT00030602	PHASE2	COMPLETED	Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer
NCT00031733	PHASE2	COMPLETED	Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma
NCT00032045	PHASE2	COMPLETED	Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma
NCT00059475	PHASE2	COMPLETED	Peptide Vaccination for Patients at High Risk for Recurrent Melanoma
NCT00062036	PHASE1/PHASE2	COMPLETED	Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma
NCT00071981	PHASE2	COMPLETED	Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma
NCT00072085	PHASE2	COMPLETED	Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma
NCT00077532	PHASE2	COMPLETED	Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma
NCT00079144	PHASE2	COMPLETED	Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma
NCT00080353	PHASE2	COMPLETED	Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma
NCT00085189	PHASE2	COMPLETED	Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
NCT00089063	PHASE2	COMPLETED	Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma
NCT00089193	PHASE2	COMPLETED	Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
NCT00089206	PHASE2	COMPLETED	Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
NCT00104780	PHASE2	UNKNOWN	Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
NCT00109811	PHASE2	COMPLETED	Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer
NCT00118274	PHASE1/PHASE2	COMPLETED	Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
NCT00184067	PHASE2	TERMINATED	Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma
NCT00295958	PHASE2	COMPLETED	LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery
NCT00303836	PHASE2	TERMINATED	Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).